Rein Therapeutics Inc. (RNTX)
| Market Cap | 90.36M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -50.21M |
| Shares Out | 93.04M |
| EPS (ttm) | -1.82 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 331,059 |
| Open | 0.917 |
| Previous Close | 0.935 |
| Day's Range | 0.898 - 0.975 |
| 52-Week Range | 0.864 - 2.180 |
| Beta | 1.35 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About RNTX
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company’s lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company’s pipeline also includes preclinical programs ... [Read more]
Financial Performance
Financial StatementsNews
Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom
16 patients enrolled to date in trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) First patient randomized in the United Kingdom Clinical trial sites now actively enrolling in the United States, ...
Rein Therapeutics Proxy statement: Proxy filing
Rein Therapeutics filed a proxy statement on June 8, 2026, providing details for shareholder voting and corporate governance matters.
Rein Therapeutics Proxy statement: Proxy filing
Rein Therapeutics filed a proxy statement on June 8, 2026, providing details for shareholder voting and corporate governance matters.
Rein Therapeutics price target lowered to $8 from $10 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Rein Therapeutics (RNTX) to $8 from $10 and keeps a Buy rating on the shares post the Q1 report. The firm cites…
Rein Therapeutics Proxy statement: Proxy filing
Rein Therapeutics filed a proxy statement on May 28, 2026, providing details for shareholder voting and corporate governance matters.
Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option
Total gross proceeds increased to $57.5 million Offering consisted solely of common stock Proceeds expected to fund Phase 2 trial of LTI-03 in IPF through completion and support operations into 2028 A...
Rein Therapeutics Quarterly report: Q1 2026
Rein Therapeutics has published its Q1 2026 quarterly earnings report on May 15, 2026.
Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock
AUSTIN, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (NASDAQ: RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-cl...
Rein Therapeutics provides update on RENEW clinical trial
Rein Therapeutics (RNTX) provided an update on its ongoing Phase 2 RENEW clinical trial evaluating LTI-03 for the treatment of idiopathic pulmonary fibrosis. The company said, “The Company has enrolle...
Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis
Patient enrollment accelerates across expanding number of clinical trial sites in multiple countries 8 patients enrolled, with additional patients expected in the near term Enrollment initiated in Mar...
Rein Therapeutics files to sell 30M shares of common stock
Konik Capital Partners is acting as manager.
Rein Therapeutics Registration statement: Registration filing
Rein Therapeutics filed a registration statement on April 28, 2026, providing details about a securities offering with the SEC.
Rein Therapeutics past the regulatory uncertainty, says H.C. Wainwright
H.C. Wainwright reiterates a Buy rating on Rein Therapeutics (RNTX) with a $10 price target after the company said it dosed the first patient in its Phase 2 clinical trial…
Rein Therapeutics Annual report: Q4 2025
Rein Therapeutics has published its Q4 2025 annual report on March 26, 2026.
Rein Therapeutics downgraded to Hold from Buy at Brookline
Brookline downgraded Rein Therapeutics (RNTX) to Hold from Buy, citing near-term financing risk.
Rein Therapeutics Slides: Corporate presentation
Rein Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on January 21, 2026.
Rein Therapeutics receives orphan drug designation from EMA for LTI-03
Rein Therapeutics (RNTX) announced that it has received orphan drug designation from the European Medicines Agency, EMA, for LTI-03, its lead drug candidate aimed at preserving lung function in patien...
Rein Therapeutics Quarterly report: Q3 2025
Rein Therapeutics has published its Q3 2025 quarterly earnings report on November 14, 2025.
Rein Therapeutics announces publication on LTI-03
Rein Therapeutics (RNTX) announced that a new preprint has been posted to medRxiv describing clinical and translational findings from an inhaled, dose-escalation study of Rein’s lead drug candidate, L...
Rein Therapeutics upgraded to Buy from Hold at Brookline
Brookline upgraded Rein Therapeutics (RNTX) to Buy from Hold with a $6 price target
Rein Therapeutics receives FDA clearance to resume Phase 2 trial of LTI-03
Rein Therapeutics (RNTX) announced that the U.S. Food and Drug Administration has lifted the full clinical hold on the Company’s Phase 2 “RENEW” trial evaluating LTI-03 in patients with idiopathic…
Rein receives European regulatory approval to initiate Phase 2 trial of LTI-03
Rein Therapeutics (RNTX) announced that it has received authorization from the European Medicines Agency, EMA, to initiate the Company’s Phase 2 “RENEW” clinical trial of its lead candidate, LTI-03, f...
Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
AUSTIN, Texas, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant un...
Rein Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Brandon Folkes initiated coverage of Rein Therapeutics (RNTX) with a Buy rating and $10 price target The shares can outperform over the next 12 months given the…
Rein Therapeutics announces publication of data on LTI-03 in IPF
Rein Therapeutics (RNTX) announced the publication of novel data on its lead drug candidate, LTI-03, in iScience, a peer-reviewed, open-access journal published by Cell Press. The paper, titled “LTI-0...